Harvard Pilgrim Health Care | TUFTS Health Plan

Pharmacy Medical Necessity Guidelines: **Simponi® (golimumab) Subcutaneous**

Effective: December 12, 2023

Guideline Type	☒ Prior Authorization ☐ Non-Formulary ☐ Step-Therapy ☐ Administrative

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products; Fax: 617-673-0988

☒ Tufts Health Plan Commercial products; Fax: 617-673-0988

CareLink℠ – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

Public Plans Products

☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax: 617-673-0988

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration – Approved Indications

Simponi (golimumab) subcutaneous is a tumor necrosis factor blocker indicated for:

Disease State	
Ankylosing Spondylitis	X
Psoriatic Arthritis	X
Rheumatoid Arthritis	X
Ulcerative Colitis	X

Clinical Guideline Coverage Criteria

The plan may authorization coverage of Simponi subcutaneous for Members when all of the following criteria are met:

Ankylosing Spondylitis

1. Documented diagnosis of ankylosing spondylitis

AND

2. Patient is at least 18 years of age

AND

3. Prescribed by or in consultation with a rheumatologist

AND

4. Documentation of **one (1)** of the following:
   a. Inadequate response or adverse reaction to a prescription strength non-steroidal anti-inflammatory drug (e.g., celecoxib, diclofenac, ibuprofen, naproxen, meloxicam)
   b. Contraindication to non-steroidal anti-inflammatory drugs
   c. Previous treatment with a biologic agent indicated for the requested use
   d. The patient is new to the plan and has been stable on the requested agent prior to enrollment

Psoriatic Arthritis

1. Documented diagnosis of psoriatic arthritis

AND

2. Patient Is at least 18 years of age

AND

3. Prescribed by or consultation with a rheumatologist or dermatologist

Rheumatoid Arthritis

1. Documented diagnosis of rheumatoid arthritis

AND

2. Patient is at least 18 years of age

AND

3. Prescribed by or in consultation with a rheumatologist

AND

4. Documentation of **one (1)** of the following:
    a. Inadequate response or adverse reaction to one disease modifying antirheumatic drug (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine)
    b. Contraindication to all traditional disease modifying antirheumatic drugs
    c. Previous treatment with a biologic agent indicated for the requested use
    d. The patient is new to the plan and has been stable on the requested agent prior to enrollment

Ulcerative Colitis

1. Documented diagnosis of ulcerative colitis

AND

2. Patient is at least 18 years of age

AND

3. Prescribed by or in consultation with a gastroenterologist

AND

4. Documentation of **one (1)** of the following:
    a. Inadequate response or adverse reaction to a corticosteroid, a 5-aminosalycylate, 6-mercaptopurine, or methotrexate
    b. Contraindication to corticosteroids, 5-aminosalycylates, 6-mercaptopurine, and methotrexate
    c. The patient is moderate to high risk as evidenced by deep ulcers on colonoscopy, long segments of small and/or large bowel involvement, perianal disease, extra-intestinal manifestations (e.g., fever, weight loss, abdominal pain, intermittent nausea/vomiting), history of bowel resections, or recent hospitalization for the disease
    d. Previous treatment with a biologic agent indicated for the requested use
    e. The patient is new to the plan and has been stable on the requested agent prior to enrollment

Limitations

1. Samples, free goods, or similar offerings of the requested medication do not qualify for an established clinical response and will not be considered for prior authorization.
2. Documentation of a Member being a social drinker does not qualify as a medically acceptable contraindication or clinical inappropriateness to methotrexate therapy.

Codes

None

References

1. Simponi (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; September 2019.
2. Inman RD, Davis JC, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Arthritis & Rheumatism. 2008; 58(11): 3402-3412.

3. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis & Rheumatism. 2009; 60(4): 976-986.
4. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939.
5. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72.
6. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32. HPHC Pharmacy PA Policy: Page 5 of 5.
7. Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS/EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76: 978-991.
8. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019; 71:1599.
9. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019; 114:384.
10. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterol. 2020;158:1450- 1461.

Approval And Revision History

September 13, 2022: Reviewed by the Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- September 2022 e-vote: Effective January 1, 2023, Enbrel added as a preferred agent.
- December 12, 2023: No changes

Background, Product and Disclaimer Information

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member’s benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.